Gut health.
BPC-157 is the best-evidenced peptide for gut health — it is the only peptide on PEPTIDEX whose native biological source is human gastric juice, and its gastrointestinal research base is deeper than for any other tissue type. KPV complements BPC-157 with PepT1-mediated anti-inflammatory signaling directly in intestinal epithelium, backed by a Gastroenterology-published mechanism study.
The Gut Health stack.
A balanced protocol engineered for gut health via targeted peptide synergy.
2 peptides, precisely sequenced.
Each peptide plays a specific role. Removing any one breaks the synergy.
Injury recovery, gut healing, tissue repair, reduced inflammation
Customize this protocol
Open this protocol in the Cycle Planner to adjust duration, swap peptides, and generate your reference dosing chart.
Based on published trial data.
GI Mucosal Defense: The Two-Layer Protection Model
The gastrointestinal tract's defensive capacity against ulceration, inflammation, and permeability breakdown operates through two distinct but complementary mechanisms: active tissue repair at the mucosal surface (driven by growth factor signaling, angiogenesis, and cell migration), and epithelial anti-inflammatory signaling that attenuates the immune cascades that perpetuate gut inflammation even after the initial insult is resolved. BPC-157 operates primarily on the first layer; KPV operates primarily on the second. Together they address the full arc of GI repair from acute mucosal injury through chronic inflammatory resolution.
TIER 1 — BPC-157: Origin in Gastric Juice, Strongest Evidence in Gut
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a naturally occurring protein in human gastric juice. This origin is not incidental: BPC-157 is the only peptide on the PEPTIDEX platform whose native biological context is the gastrointestinal tract. Its discovery emerged from research on the cytoprotective properties of gastric juice constituents, and the strongest evidence across all BPC-157 research — stronger than the tendon, bone, or neurological evidence — is in GI applications.
BPC-157 mechanism in the GI tract involves: (1) stimulation of VEGF-mediated angiogenesis at the mucosal surface, accelerating the restoration of the vascular supply that underlies mucosal healing; (2) upregulation of growth hormone receptor expression at the site of injury, amplifying local tissue repair signaling; (3) modulation of NO (nitric oxide) synthase activity to maintain the vasodilatory tone that sustains mucosal blood flow under inflammatory conditions; and (4) direct cytoprotective activity against a broad spectrum of GI insults including NSAID-induced gastric damage, ethanol-induced mucosal lesions, and ischemia-reperfusion injury. The cytoprotective breadth is the defining feature: BPC-157 demonstrates consistent protective activity against mechanistically distinct GI insults through multiple converging pathways. A 2018 review in Current Pharmaceutical Design (PMID: 29879879) characterized BPC-157 as a novel cytoprotective mediator specifically in the context of vascular recruitment and GI tract healing.
In colitis and IBD research, BPC-157 has been evaluated in both preclinical models and has reached formal clinical trial status. A 2006 review in Inflammopharmacology (PMID: 17186181) documented BPC-157 in trials for inflammatory bowel disease under the designations PL-10, PLD-116, and PL 14736 by Pliva Pharmaceuticals, Zagreb. A 2013 study in J Physiol Pharmacol (PMID: 24304574) demonstrated BPC-157 healing cysteamine-induced colitis and colon anastomosis healing in animal models. A 2012 review in Current Medicinal Chemistry (PMID: 22300085) focused specifically on BPC-157 in ulcerative colitis. The 2017 Curr Pharm Des paper (PMID: 28228068) addressed the gut-brain axis connection, documenting BPC-157 counteracting stress-induced GI dysfunction. This is the most evidence-dense page for BPC-157 across the entire /best/ directory — because this is where the compound's evidence actually lives.
TIER 2 — KPV: PepT1-Mediated Epithelial Anti-Inflammatory Signaling
KPV (Lys-Pro-Val) is a tripeptide fragment of the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike its ambiguous musculoskeletal evidence profile (disclosed honestly on the healing page), KPV has genuinely substantive gut-specific evidence anchored in a well-characterized transport mechanism: uptake via the PepT1 peptide transporter, which is expressed on intestinal epithelial cells and preferentially transports short peptides from the intestinal lumen into the epithelium.
The Dalmasso et al. (2008) study in Gastroenterology (PMID: 18061177) is the primary citation: a major-journal publication demonstrating that PepT1-mediated KPV uptake directly reduces intestinal inflammation through NF-kB pathway inhibition in intestinal epithelial cells. This is the mechanistic foundation: KPV is taken up selectively by inflamed intestinal epithelium (where PepT1 is upregulated during inflammation) and suppresses the nuclear factor kappa-B inflammatory cascade at the epithelial level, attenuating the inflammatory amplification loop that sustains chronic GI inflammation. A 2016 study in Cell Mol Gastroenterol Hepatol (PMID: 27458604) extended this, demonstrating KPV therapeutic benefit in colitis-associated cancer via the same PepT1 pathway. KPV evidence is in colitis research specifically, not in general gut optimization or healthy-gut maintenance — the framing here reflects that distinction. KPV addresses active gut inflammation; BPC-157 addresses the full repair arc including non-inflammatory injury.
Research Evidence for Gut-Health Peptides
BPC-157 has the most extensive peer-reviewed GI research of any peptide on this platform — a research program spanning 30+ years at the University of Zagreb under the Sikiric group, producing dozens of PubMed-indexed publications across multiple GI indications. The evidence cited here focuses on the strongest GI-specific papers. KPV GI evidence is more limited but includes high-tier journal publications with clear mechanistic grounding.
BPC-157: The Sikiric Research Program
The BPC-157 GI research base originates with Predrag Sikiric and colleagues at the University of Zagreb, Croatia. This is important to characterize correctly: unlike Semax and Selank (where the evidence is primarily from the Russian Academy of Sciences with limited Western journal indexing), the Sikiric BPC-157 research program has been consistently published in PubMed-indexed, peer-reviewed international journals across the pharmaceutical and physiology literature. The evidence is Western-journal-indexed Croatian academic research, not Russian-language-only literature. The distinction matters for citation policy: BPC-157 GI papers can be cited as primary registry PMIDs, not passive attribution.
The evidence landscape: BPC-157 was evaluated in formal pharmaceutical clinical trial programs by Pliva Pharmaceuticals (Zagreb) for IBD, reaching phase II/III designation under the PL-10 and related identifiers (PMID: 17186181). A 2018 comprehensive review (PMID: 29879879) positioned BPC-157 as a novel cytoprotective mediator with vascular recruitment mechanisms distinct from existing GI therapies. The 2013 colitis healing study (PMID: 24304574) demonstrated BPC-157 accelerating healing in both chemically-induced colitis and surgical anastomosis in animal models. The 2012 ulcerative colitis review (PMID: 22300085), the 2016 brain-gut axis review in Current Neuropharmacology (PMID: 27138887), and the 2017 gut-brain/stress review (PMID: 28228068) complete the evidence picture across three GI-relevant domains: IBD/colitis, brain-gut axis bidirectional signaling, and stress-induced GI dysfunction. Note: despite the clinical trial history, BPC-157 does not hold regulatory approval in the US, EU, or Australia for any GI indication. The Pliva trials did not result in market authorization. Current status: investigational/research-only.
KPV: High-Tier Journal Evidence for a Specific Mechanism
The Gastroenterology 2008 publication (PMID: 18061177) represents the highest journal-tier citation for KPV across any application on this platform. Gastroenterology is the flagship journal of the American Gastroenterological Association and one of the two highest-impact journals in the GI field. The paper directly established that PepT1-mediated KPV uptake reduces intestinal inflammation through NF-kB inhibition in intestinal epithelial cells — a clear, direct demonstration of mechanism and effect in a highly relevant tissue. The 2016 Cell Mol Gastroenterol Hepatol study (PMID: 27458604) extended the findings to colitis-associated cancer, demonstrating that KPV suppression of the PepT1/NF-kB pathway reduces cancer-promoting inflammation in the colitis context. Both studies are rodent-model research; no human RCT for KPV in IBD or gut inflammation has been published. The mechanism is well-characterized; the clinical translation remains unconfirmed.
Tracking Gut Health Outcomes
GI improvement metrics span subjective symptom scales and objective biomarkers. Tracking should be stratified by whether the goal is acute gut injury recovery (BPC-157 primary focus), chronic IBD/colitis management research context (BPC-157 + KPV), or general gut optimization.
- Bristol Stool Form Scale (BSFS) Daily Log: The most accessible daily gut health metric. BSFS types 3-4 represent healthy transit; types 1-2 indicate constipation; types 6-7 indicate loose/inflammatory stool patterns. Photograph-based or self-rating app tracking over 4-8 weeks captures the stool consistency trend that reflects mucosal health and transit time. A successful BPC-157 protocol should trend toward BSFS 3-4 from aberrant baselines within 2-4 weeks.
- Gastrointestinal Symptom Rating Scale (GSRS): Validated 15-item questionnaire covering reflux, abdominal pain, indigestion, diarrhea, and constipation syndromes. Available free online. Baseline before protocol; at 4-week intervals. GSRS provides a composite symptom score that is more comprehensive than single-metric tracking and directly maps to the BPC-157 cytoprotection evidence (which covers acid-related, NSAID-induced, and IBD-type GI pathology).
- Fecal Calprotectin (if IBD-context research): Fecal calprotectin is a neutrophil-derived protein that is elevated in active intestinal inflammation. It is the most accessible non-invasive biomarker for distinguishing inflammatory GI disease from functional GI symptoms. For subjects using BPC-157 + KPV in an IBD research context, fecal calprotectin at baseline and 8 weeks provides the most direct evidence of anti-inflammatory effect. Normal: below 50 mg/kg; elevated: above 200 mg/kg. Calprotectin test kits are available without prescription in most markets.
- CRP and ESR (systemic inflammation markers): C-reactive protein and erythrocyte sedimentation rate provide systemic correlates of gut inflammation in IBD-spectrum conditions. Useful as secondary biomarkers alongside fecal calprotectin. Note: CRP and ESR are non-specific and reflect systemic inflammation from any source, not gut-specific activity.
- Gut Permeability Markers (Zonulin, LPS-binding protein): For subjects targeting leaky gut/intestinal permeability specifically, serum zonulin and LPS-binding protein provide indirect markers of tight junction integrity. Zonulin assays are commercially available. Note: zonulin methodology has reliability limitations; the assay should be used as a trend marker over time rather than an absolute diagnostic value.
Alternative Approaches to Gut Health
BPC-157 and KPV address the mucosal repair and epithelial anti-inflammatory layers of gut health. The alternatives below address complementary layers: microbiome composition, tight junction integrity, and mucosal nutrition supply.
The High-Evidence Non-Peptide Gut Foundation
Before any peptide gut protocol, the dietary and microbiome baseline should be characterized. The highest-evidence interventions for general gut health maintenance are: dietary fiber adequacy (25-38g/day from diverse plant sources, supporting microbiome diversity and short-chain fatty acid production); fermented food intake (yogurt, kefir, kimchi, sauerkraut at 1-2 servings/day, with the strongest human evidence for microbiome diversity improvement from the Sonnenburg lab SSFC trial); and elimination of the specific dietary trigger (gluten for celiac, FODMAPs for IBS-FODMAP-sensitive, NSAIDs for drug-induced mucosal damage). If the gut health issue has a clear dietary driver and dietary intervention is not in place, peptide protocols are augmenting an unresolved upstream problem.
Probiotics and Prebiotics: Specific Strain Evidence
The probiotic literature is plagued by strain-specificity problems: most probiotic marketing generalizes findings from specific studied strains to entire genera or species. The evidence-based approach is strain-specific: Lactobacillus rhamnosus GG (LGG) has the strongest pediatric diarrhea prevention and antibiotic-associated diarrhea evidence. Saccharomyces boulardii CNCM I-745 has the strongest adult antibiotic-associated diarrhea and C. difficile prevention evidence. Multi-strain combinations lack the specificity of single-strain evidence but have practical accessibility advantages. Prebiotic fiber (inulin, FOS, GOS) at 5-15g/day provides substrate for existing beneficial microbiota without the colonization uncertainty of probiotic supplements. BPC-157 and KPV address mucosal tissue pathology; probiotics address microbiome composition. They target different failure modes and are not competitive alternatives.
L-Glutamine: Enterocyte Primary Fuel and Mucosal Maintenance
L-Glutamine is the primary metabolic fuel for intestinal enterocytes and colonocytes. During high physiological stress (surgery, critical illness, intense athletic training, IBD flare), glutamine demand in the gut exceeds systemic supply, contributing to mucosal breakdown. Supplemental L-glutamine (10-30g/day in clinical nutrition contexts; 5-10g/day in research protocols for gut optimization) supports enterocyte energy availability and tight junction protein expression. Human evidence for glutamine in clinical GI settings (post-surgical gut permeability, critical illness mucosal protection) is relatively strong; evidence in healthy athlete populations is mixed. Glutamine and BPC-157 address the same mucosal repair endpoint through different mechanisms (nutrient supply vs. growth factor signaling); they are complementary rather than redundant.
Zinc Carnosine: Mucosal Adherence and Gastric Protection
Zinc L-carnosine (Polaprezinc) is a chelated compound combining zinc and carnosine that adheres to the gastric and intestinal mucosal surface, providing sustained local zinc delivery. It has Japanese regulatory approval for peptic ulcer treatment (as Promac) and is available as a supplement in most Western markets. Multiple small RCTs have demonstrated zinc carnosine improving markers of gut permeability (lactulose/mannitol ratio), reducing NSAID-induced small intestinal damage, and supporting mucosal healing in H. pylori eradication contexts. The mucosal adherence mechanism makes zinc carnosine a directly complementary adjunct to BPC-157 mucosal repair protocols: BPC-157 drives growth factor-mediated repair from the systemic/submucosal side; zinc carnosine provides local mineral support from the luminal side.
Larazotide Acetate (Research Context): Tight Junction Regulation
Larazotide acetate (AT-1001) is a synthetic octapeptide that regulates tight junction assembly by blocking the zonulin receptor. It was developed for celiac disease (to reduce gluten-induced tight junction opening) and reached phase II/III clinical trials. Results showed modest but statistically significant reductions in intestinal permeability markers and celiac symptom improvement versus placebo in some trials. Larazotide is a different mechanistic class from BPC-157 and KPV: it targets the tight junction structural protein network directly rather than mucosal repair or epithelial anti-inflammatory signaling. It belongs in the alternatives section because it is not a general gut health research peptide (celiac-specific indication) and regulatory approval has not been achieved. Research context only.
- Sikiric P et al. (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736). Inflammopharmacology. PubMed
- Sikiric P et al. (2018). Novel Cytoprotective Mediator BPC 157: Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. PubMed
- Sikiric P et al. (2013). BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone ovariectomy. J Physiol Pharmacol. PubMed
- Sikiric P et al. (2012). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. PubMed
- Sikiric P et al. (2017). Stress in Gastrointestinal Tract and BPC 157: do we have a Solution? Curr Pharm Des. PubMed
- Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed
- Dalmasso G et al. (2016). Critical role of PepT1 in colitis-associated cancer and therapeutic benefits of KPV. Cell Mol Gastroenterol Hepatol. PubMed
- Sikiric P et al. (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. PubMed
Estimated total cost for the Gut Health stack (2 compounds) across verified vendors.
Totals are estimates — individual products must be added at vendor checkout. Affiliate links · Rankings independent.
Frequently asked questions.
Why is BPC-157 particularly relevant to gut health specifically?
BPC-157 was isolated from human gastric juice - its native biological source is the gastrointestinal tract. This origin is meaningful: the gastric mucosal environment where BPC-157 naturally occurs is precisely the tissue it protects most potently. The research program from the Sikiric group at the University of Zagreb has produced more PubMed-indexed GI-specific publications for BPC-157 than for any other tissue type. BPC-157 reached formal pharmaceutical clinical trials for IBD (under PL-10, PLD-116 designations by Pliva Pharmaceuticals, Zagreb) - a clinical development milestone that musculoskeletal BPC-157 applications have not reached. The gut is where this compound evidence lives. → Read more at peptidex.app/library/bpc-157
What is the difference between BPC-157 and KPV in gut health applications?
BPC-157 drives mucosal repair from the vascular and growth-factor level: it stimulates VEGF-mediated angiogenesis to restore mucosal blood supply, upregulates growth hormone receptors at the injury site, and provides cytoprotection against a broad range of GI insults (NSAID damage, ethanol-induced lesions, ischemia-reperfusion). KPV targets the epithelial anti-inflammatory layer: it is taken up selectively by inflamed intestinal epithelium via the PepT1 transporter and suppresses NF-kB-mediated inflammatory signaling at the epithelial level (PMID: 18061177). BPC-157 = mucosal repair. KPV = epithelial inflammation attenuation. Different failure modes, complementary mechanisms.
Has BPC-157 been in human clinical trials for gut health?
Yes - BPC-157 reached clinical trial status for inflammatory bowel disease under pharmaceutical development by Pliva Pharmaceuticals, Zagreb, Croatia (PMID: 17186181). The compound was evaluated under the designations PL-10, PLD-116, and PL 14736 in IBD trials. This is a higher level of clinical development than most research peptides achieve. However, BPC-157 did not receive market authorization from the trials - it does not hold regulatory approval for any GI indication in the US, EU, or Australia. Current status remains investigational/research-only despite the pharmaceutical trial history.
What is KPV and how does it enter gut tissue?
KPV (Lys-Pro-Val) is a tripeptide fragment of the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). It enters intestinal epithelial cells via PepT1 (Peptide Transporter 1), an intestinal transporter that normally handles dietary di- and tripeptides from the gut lumen. Crucially, PepT1 is upregulated during intestinal inflammation - meaning KPV uptake is selectively enhanced precisely at inflamed sites. Once inside epithelial cells, KPV inhibits NF-kB activation, reducing the production of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) that sustain the chronic inflammatory loop in conditions like IBD. Evidence in Gastroenterology (PMID: 18061177) and Cell Mol Gastroenterol Hepatol (PMID: 27458604). → Read more at peptidex.app/library/kpv
What does gut-brain axis mean in the BPC-157 context?
The gut-brain axis refers to the bidirectional communication between the enteric nervous system (the gastrointestinal tract nervous system) and the central nervous system. Chronic gut inflammation and mucosal permeability disruption are associated with CNS effects via vagal nerve signaling, systemic inflammatory cytokine production, and altered microbiome metabolite generation (short-chain fatty acids, neurotransmitter precursors). BPC-157 has been studied in the context of stress-induced GI dysfunction (PMID: 28228068), which addresses the reverse pathway: chronic psychological stress causing GI mucosal breakdown. BPC-157 counteracts stress-induced GI dysfunction in animal models, suggesting relevance to the anxiety/stress-driven gut problems (IBS-stress subtype, functional dyspepsia) as well as direct GI pathology.
How does BPC-157 compare to PPI (proton pump inhibitor) therapy for gastric issues?
Completely different mechanisms. PPIs (omeprazole, pantoprazole) suppress gastric acid secretion by blocking the H+/K+ ATPase pump in parietal cells - they reduce the acidic insult to the mucosal surface but do not repair existing damage or restore mucosal integrity. BPC-157 does not affect acid secretion but directly promotes cytoprotective and repair mechanisms at the mucosal surface. For NSAID-induced mucosal damage specifically, BPC-157 cytoprotection in animal models operates even when acid is not the primary mechanism of injury - suggesting complementary rather than equivalent activity. PPIs are regulatory-approved treatments for peptic ulcer, GERD, and related conditions; BPC-157 is research-only. Not a replacement; potentially a mechanistically complementary research adjunct.
Is BPC-157 appropriate for H. pylori-related gut issues?
BPC-157 addresses mucosal damage caused by H. pylori-induced gastric inflammation, not H. pylori eradication itself. Active H. pylori infection requires antibiotic eradication therapy (standard triple therapy: PPI + clarithromycin + amoxicillin). BPC-157 cytoprotective mechanisms are relevant to the mucosal repair phase following successful H. pylori eradication - the period during which the gastric mucosa recovers from the chronic inflammatory damage. Using BPC-157 during active H. pylori infection without concurrent antibiotic eradication addresses the wound without removing the cause. Confirm H. pylori status (breath test or fecal antigen) before designing any gut peptide protocol.
Can BPC-157 and KPV be combined in a gut protocol?
Yes - the mechanistic complementarity is the justification for the 2-tier structure on this page. BPC-157 operates at the vascular/submucosal repair layer via VEGF and growth hormone receptor upregulation; KPV operates at the epithelial anti-inflammatory layer via PepT1/NF-kB. The combination addresses the full arc from acute mucosal injury through chronic inflammatory resolution. No pharmacological antagonism between the compounds. In colitis-context research, the rationale for combining them is strongest: BPC-157 for anastomotic and mucosal healing, KPV for epithelial inflammation attenuation during the chronic phase.
What is the administration route for BPC-157 in gut health applications?
Both oral and subcutaneous BPC-157 have been studied in GI research. Oral administration is mechanistically plausible for gut-specific applications: BPC-157 is resistant to gastric acid degradation (unlike most peptides), which is consistent with its origin from gastric juice. Research protocols for GI applications have used both routes. For systemic effects (e.g., gut-brain axis, systemic cytoprotection), subcutaneous is more consistent. For localized gastric mucosal protection and healing, oral may have a logical advantage given direct mucosal contact. Current research has not definitively established route superiority for GI indications. This is an area where clinical trial data would be definitive; that data does not yet exist.
What are the main safety considerations for BPC-157 and KPV in gut applications?
BPC-157 safety profile in the research literature is generally favorable: the Sikiric research program spanning decades has not documented dose-limiting toxicity in animal models at pharmacological doses. The clinical trial program under Pliva did not advance due to efficacy/commercial reasons, not safety signals (from the available literature). KPV as a tripeptide fragment of endogenous alpha-MSH has favorable theoretical safety profile. Neither compound holds regulatory approval for any indication; Western regulatory status is research-only for both. COA-verified purity (above 99%) is essential. GI peptide research context: any gut health intervention, peptide or otherwise, should be evaluated in the context of known underlying pathology. Active GI bleeding, recent gut surgery, or undiagnosed GI symptoms warrant clinical evaluation before research peptide protocols.
Is there a discount on research-grade BPC-157 and KPV for gut health protocols?
Yes. The PEPTIDEX coupon code provides a verified discount at COA-verified vendors who supply research-grade BPC-157 and KPV. The code applies at checkout at partner vendors listed on the PEPTIDEX deals page. Purity verification (COA showing ≥99% by HPLC) matters more than price — the vendor comparison table on PEPTIDEX filters for COA-verified sources only, so the discount applies exclusively to quality-verified supply. → See peptidex.app/peptidex-coupon for current terms and peptidex.app/deals for eligible vendors.